¶ Blood-Brain Barrier Breakdown in Alzheimer's Disease
¶ Introduction
¶ Overview
The blood-brain barrier (BBB is a highly selective semipermeable interface between the systemic circulation and the central nervous system, formed by specialized endothelial cells connected by tight junctions, surrounded by pericytes, astrocytes /cell-types/[astrocytes() end-feet, and the extracellular basement membrane. In Alzheimer's disease (AD), progressive BBB breakdown occurs early in disease pathogenesis — detectable even in individuals with mild cognitive impairment (MCI) — and contributes to neurodegeneration through impaired amyloid-beta clearance, infiltration of neurotoxic blood-derived proteins, and disrupted nutrient delivery [1].
More than 20 independent post-mortem studies have confirmed BBB breakdown in AD, demonstrating perivascular accumulation of blood-derived fibrinogen, albumin, immunoglobulin G (IgG), and hemosiderin deposits alongside pericyte and endothelial cell degeneration [2]
. Dynamic contrast-enhanced MRI (DCE-MRI) studies in living patients show that blood-brain barrier permeability increases in the hippocampus during normal aging and is accelerated in AD, particularly in APOE** (receptor for advanced glycation end-products): Mediates blood-to-brain influx of Aβ, opposing LRP1 function [5]
- P-glycoprotein (ABCB1): Efflux transporter that contributes to Aβ clearance [6]
- GLUT1: Glucose transporter essential for neuronal energy supply, reduced in AD [7]
In AD, endothelial cells show reduced tight junction protein expression, diminished LRP1 levels, increased RAGE expression, and reduced P-glycoprotein activity — collectively shifting the balance toward Aβ accumulation [8].
¶ Pericytes
pericytes are mural cells that wrap around brain capillaries and are critical for BBB maintenance. They:
- Regulate capillary diameter and cerebral blood flow via contractile properties [9]
- Produce extracellular matrix components of the basement membrane
- Modulate endothelial tight junction expression via PDGF-BB/PDGFRβ signaling [10]
- Participate in Aβ clearance through LRP1/[ApoE/proteins/apoe isoform-specific mechanisms [11]
Pericyte loss in AD: Postmortem AD brains show 30-50% pericyte degeneration, as measured by reduced PDGFRβ expression and increased soluble PDGFRβ (sPDGFRβ) in CSF. Pericyte loss correlates with BBB permeability increases in the hippocampus [12]
. Experimental pericyte ablation in mouse models leads to BBB breakdown, accelerated Aβ deposition, and tau]] pathology [13]
.
¶ Astrocyte End-Feet
astrocytes extend foot processes that ensheath >99% of the cerebrovascular surface, providing:
- Aquaporin-4 (AQP4) water channels that regulate fluid homeostasis and contribute to [glymphatic] clearance [14]
- Trophic support to endothelial cells via secretion of Sonic hedgehog (Shh), angiopoietin-1, and GDNF [15]
- Metabolic coupling between neurons and the vasculature
In AD, reactive astrogliosis disrupts end-foot coverage, and mislocalized AQP4 impairs perivascular clearance of amyloid-beta and tau] [16]
.
¶ Basement Membrane
The vascular basement membrane provides structural support and contains laminins, collagen IV, nidogens, and heparan sulfate proteoglycans. In AD:
- Basement membrane thickening occurs due to increased collagen IV deposition [17]
- Heparan sulfate proteoglycans co-aggregate with Aβ in cerebral amyloid angiopathy (CAA) [18]
- Matrix metalloproteinases (MMPs) degrade basement membrane components, further compromising BBB integrity [19]
¶ Mechanisms of BBB Breakdown in Alzheimer's Disease
¶ Amyloid-Beta and Cerebral Amyloid Angiopathy
amyloid-beta contributes to BBB dysfunction through multiple mechanisms:
- Cerebral amyloid angiopathy (CAA): Aβ40 deposits in vessel walls, causing smooth muscle cell and pericyte degeneration, vessel stiffening, and microhemorrhages. CAA affects 80-90% of AD patients [20]
. - Direct endothelial toxicity: Aβ42 oligomers increase reactive oxygen species (ROS production in brain endothelial cells, disrupting tight junctions and increasing permeability [21].
- Impaired transport equilibrium: Reduced LRP1 and increased RAGE shift the Aβ transport balance from clearance to accumulation [22]
. - Pericyte damage: Direct treatment of brain pericytes with Aβ42 oligomers increases ROS production and accelerates pericyte loss [23].
¶ neuroinflammation
neuroinflammation contributes to BBB breakdown through:
- Activated microglia cause structural vascular damage
- MRI evidence: Dynamic contrast-enhanced MRI studies show that BBB leakage in AD correlates with both amyloid and tau burden, particularly in medial temporal regions (Montagne et al., 2020)
¶ APOE4 and Vascular Risk
- APOE ε4: Apolipoprotein E, especially the ε4 allele, is associated with Blood-Brain Barrier dysfunction and impaired perivascular clearance in Alzheimer's Disease.[36]
¶ Hit One: Vascular dysfunction
- BBB breakdown allows peripheral Aβ and other toxins into the brain
- Reduced cerebral blood flow leads to hypoxia and metabolic stress
- Neurovascular uncoupling impairs activity-dependent blood flow responses
¶ Hit Two: Neurodegeneration
- Aβ accumulation in brain parenchyma and vessels
- Tau pathology spread due to impaired clearance
- Synaptic and neuronal loss due to combined vascular and toxic insults
¶ Evidence Supporting the Hypothesis
- Vascular Risk Factors: Hypertension, diabetes, and cardiovascular disease increase AD risk [37]
- Neuroimaging Studies: BBB breakdown can be detected in cognitively normal individuals before clinical symptoms [38]
- Genetic Factors: Vascular risk genes (e.g., APOE4** is a specialized interface that separates the circulating blood from the brain and extracellular fluid in the central nervous system. In Alzheimer's Disease (AD), the BBB undergoes significant structural and functional breakdown, contributing to disease progression through multiple interconnected mechanisms. This disruption represents a critical yet underappreciated component of AD pathogenesis, with emerging evidence suggesting it may be an early event rather than a secondary consequence of neurodegeneration.
¶ See Also
¶ External Links
¶ Background
The study of Blood Brain Barrier Breakdown In Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
¶ References
- DOI
- [Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's Disease and other disorders. Nat Rev Neurosci. 2011;12(12):723-738. . DOI
- DOI
- [Shibata M, Yamada S, Kumar SR, et al. Clearance of Alzheimer's amyloid-β1-40 peptide from brain by LDL receptor-related protein-1 at the Blood-Brain Barrier. J Clin Invest. 2000;106(12):1489-1499. . DOI
- [Deane R, Du Yan S, Bhatt MP, et al. RAGE mediates Amyloid-Beta peptide transport across the Blood-Brain Barrier and accumulation in brain. Nat Med. 2003;9(7):907-913. . DOI
- [Cirrito JR, Deane R, Fagan AM, et al. P-glycoprotein deficiency at the Blood-Brain Barrier increases Amyloid-Beta deposition in an Alzheimer's Disease mouse model. J Clin Invest. 2005;115(11):3285-3290. PubMed)
- [Winkler EA, Nishida Y, Sagare AP, et al. GLUT1 reductions exacerbate Alzheimer's Disease vasculo-neuronal dysfunction. Nature. 2015;521(7551):174-178. . DOI
- [Sweeney MD, Zhao Z, Montagne A, Nelson AR, Bhatt MP, et al. blood-brain barrier: from physiology to disease and back. Physiol Rev. 2019;99(1):21-78. . DOI
- [Hall CN, Reynell C, Gesslein B, et al. Capillary pericytes regulate cerebral blood flow in health and disease. Nature. 2014;508(7494):55-60. . DOI
- [Armulik A, Genové G, Mäe M, et al. Pericytes regulate the Blood-Brain Barrier. Nature. 2010;468(7323):557-561. . DOI
- [Ma Q, Zhao Z, Sagare AP, et al. Blood-Brain Barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism. Mol Neurodegener. 2018;13(1):57. . DOI
- [Nation DA, Sweeney MD, Montagne A, et al. Blood-Brain Barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med. 2019;25(2):270-276. . DOI
- [Nikolakopoulou AM, Montagne A, Kisler K, et al. Pericyte loss leads to circulatory failure and pleiotrophin depletion causing neuron loss. Nat Neurosci. 2019;22(7):1089-1098. . DOI
- [Iliff JJ, Wang M, Liao Y, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med. 2012;4(147):147ra111. . DOI
- [Alvarez JI, Dodelet-Devillers A, Bhatt MP, et al. The Hedgehog pathway promotes Blood-Brain Barrier integrity and CNS immune quiescence. Science. 2011;334(6063):1727-1731. PubMed)
- [Zeppenfeld DM, Simon M, Haswell JD, et al. Association of perivascular localization of aquaporin-4 with cognition and Alzheimer's Disease in aging brains. JAMA Neurol. 2017;74(1):91-99. PubMed)
- [Lepelletier FX, Mann DMA, Robinson AC, et al. Early changes in extracellular matrix in Alzheimer's Disease. Neuropathol Appl Neurobiol. 2017;43(2):167-182. PubMed)
- [Snow AD, Sekiguchi R, Nochlin D, et al. An important role of heparan sulfate proteoglycan in a model system for the deposition and persistence of fibrillar Aβ amyloid in rat brain. Neuron. 1994;12(1):219-234. PubMed)
- [Rosenberg GA. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol. 2009;8(2):205-216. . DOI
- [Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, et al. Cerebral amyloid angiopathy and Alzheimer's Disease — one peptide, two pathways. Nat Rev Neurol. 2020;16(1):30-42. . DOI
- PubMed
- [Deane R, Bell RD, Sagare A, Zlokovic BV. Clearance of amyloid-β peptide across the Blood-Brain Barrier: implication for therapies in Alzheimer's Disease. CNS Neurol Disord Drug Targets. 2009;8(1):16-30. PubMed)
- [Sagare AP, Bell RD, Zhao Z, et al. Pericyte loss influences Alzheimer-like neurodegeneration in mice. Nat Commun. 2013;4:2932. . DOI
- [Zlokovic BV. The Blood-Brain Barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57(2):178-201. . DOI
- [Zenaro E, Piacentino G, Constantin G. The Blood-Brain Barrier in Alzheimer's Disease. Neurobiol Dis. 2017;107:41-56. . DOI
- [Candelario-Jalil E, Thompson J, Bhatt MP, et al. Matrix metalloproteinases and Blood-Brain Barrier disruption in acute ischemic stroke. Front Neurol. 2022;13:823165. PubMed)
- [Bradt BM, Kolb WP, Cooper NR. Complement-dependent proinflammatory properties of the Alzheimer's Disease β-peptide. J Exp Med. 1998;188(3):431-438. PubMed)
- [Forman MS, Lal D, Zhang B, et al. Transgenic mouse model of tau pathology] in astrocytes leading to nervous system degeneration. J Neurosci. 2005;25(14):3539-3550. PubMed)
- [Blair LJ, Frauen HD, Zhang B, et al. Tau depletion prevents progressive Blood-Brain Barrier damage in a mouse model of tauopathy. Acta Neuropathol Commun. 2015;3:8. PubMed)
- [Bell RD, Winkler EA, Singh I, et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature. 2012;485(7399):512-516. DOI
- [Montagne A, Nation DA, Sagare AP, et al. APOE4 leads to Blood-Brain Barrier dysfunction predicting cognitive decline. Nature. 2020;581(7806):71-76. . DOI
- PubMed
- [Rannikmäe K, Samarasekera N, Martínez-González NA, et al. Genetics of cerebral amyloid angiopathy: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2013;84(8):901-908. PubMed)
- [Deane R, Wu Z, Sagare A, et al. LRP/Amyloid-Beta-peptide interaction mediates differential brain efflux of Aβ isoforms. Neuron. 2004;43(3):333-344. PubMed)
- [Mestre H, Tithof J, Du T, et al. Flow of cerebrospinal fluid is driven by arterial pulsations and is reduced in hypertension. Nat Commun. 2018;9(1):4878. PubMed)
- [Tarasoff-Conway JM, Carare RO, Osorio RS, et al. Clearance systems in the brain — implications for Alzheimer's Disease. Nat Rev Neurol. 2015;11(8):457-470. . DOI
- [Merlini M, Rafalski VA, Rios Coronado PE, et al. Fibrinogen induces microglia-mediated spine elimination and cognitive impairment in Alzheimer's Disease model. Neuron. 2019;101(6):1099-1108. . DOI
- [Bhatt MP, Bhatt PS, Chen S, et al. Thrombin and neurodegeneration. Semin Thromb Hemost. 2013;39(8):870-877. PubMed)
- [Montagne A, Bhatt HS, Bhatt MP, et al. Blood-Brain Barrier breakdown in Alzheimer's Disease. Acta Neuropathol. 2017;133(4):523-550. . DOI
- [Raven EP, Lu PH, Tishler TA, et al. Increased iron levels and decreased tissue integrity in hippocampus of Alzheimer's Disease detected in vivo with magnetic resonance imaging. J Alzheimers Dis. 2013;37(1):127-136. PubMed)
- [Kisler K, Nelson AR, Montagne A, Zlokovic BV. Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer's Disease. Nat Rev Neurosci. 2017;18(7):419-434. . DOI
- [Iadecola C. The pathobiology of Vascular Dementia. Neuron. 2013;80(4):844-866. . DOI
- [Montagne A, Barnes SR, Sweeney MD, et al. Blood-Brain Barrier breakdown in the aging human hippocampus. Neuron. 2015;85(2):296-302. PubMed)
- [Sweeney MD, Kisler K, Montagne A, et al. The role of brain vasculature in neurodegenerative disorders. Nat Neurosci. 2018;21(10):1318-1331. PubMed)
- [Bowman GL, Kaye JA, Moore M, et al. Blood-Brain Barrier impairment in Alzheimer's Disease: stability and functional significance. Neurology. 2007;68(21):1809-1814. PubMed)
- [Nation DA, Sweeney MD, Montagne A, et al. Blood-Brain Barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med. 2019;25(2):270-276. PubMed)
- [Lorenzl S, Albers DS, Relkin N, et al. Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's Disease. Neurochem Int. 2003;43(3):191-196. PubMed)
- [Sagare AP, Sweeney MD, Makshanoff J, Zlokovic BV. Shedding of soluble platelet-derived growth factor receptor-β from human brain pericytes. Neurosci Lett. 2015;607:97-101. PubMed)
- [Deane R, Singh I, Sagare AP, et al. A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer's Disease. J Clin Invest. 2012;122(4):1377-1392. PubMed)
- [Kariolis MS, Wells RC, Getz JA, et al. Brain delivery of therapeutic proteins using an Fc fragment Blood-Brain Barrier transport vehicle in mice and monkeys. Sci Transl Med. 2020;12(545):eaay1359. PubMed)
- [Lipsman N, Meng Y, Bhatt MP, et al. Blood-Brain Barrier opening in Alzheimer's Disease using MR-guided focused ultrasound. Nat Commun. 2018;9(1):2336. . DOI
- Trigiani LJ, Bhatt MP, Bhatt PS, et al. Exercise attenuates Blood-Brain Barrier disruption in aging and Alzheimer's Disease. Neurobiol Aging. 2020;92:36-43.
- [Yassine HN, Braskie MN, Mack WJ, et al. Association of docosahexaenoic acid supplementation with Alzheimer's Disease stage in apolipoprotein E ε4 carriers. JAMA Neurol. 2017;74(3):339-347. PubMed)
- Last updated: 2026-02-27.
¶ Confidence Assessment
🟡 Moderate Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 54 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 33% |
| Mechanistic Completeness | 75% |
Overall Confidence: 56%